Liftstream is an executive search recruitment company in the life sciences sector
Blueprint Medicines Bolsters Senior Management
Blueprint Medicines, a company discovering and developing highly selective investigational kinase medicines for patients with genomically defined diseases, has appointed Kathryn (Kate) Haviland as Chief Business Officer, who will be responsible for the firm’s corporate strategy, business development, corporate communications and investor relations functions.
Posted in Executive Appointments
Tagged #InvestinBioMgt, Anthony Boral, BluePrint Medicines, Boston Biotech, Cambridge Massachucetts, chief business officer, Chief Medical Officer, executive appointment, gender diversity, idera pharmaceuticals, Jeff Albers, Kate Haviland, rare diseases, Sarepta, women executives
Leave a comment
PTC Therapeutics appoints Chief Medical Officer and communicates CHMP conditional decision
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Ariad, Ataluren, Chief Medical Officer, CHMP, DMD, Duchenne, Duchenne Muscular Dystrophy, EMA, europe, GSK, Iclusig, investors, MAA, market authorisation application, Murad Husain, oncology, parents, patients, phase III clinical trial, Prosensa, PTC Therapeutics, Rober J. Spiegel, Sarepta, USA, VP Global Regulatory Affairs
Leave a comment
Liftstream Attending World Orphan Drug Congress in Geneva
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Cydan, David Mott, Duchenne Muscular Dystrophy, funding, Liftstream, NEA, Orphan drugs, Prosensa, PTC Therapeutics, public private funding, Rare Disease, Sarepta, Shire, Summit, venture capital, Viropharma, WODC, world orphan drug congress
Leave a comment
Onyx deal signals broader interest in orphan drugs
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged Aegerion, Alexion, Amgen, BioMarin, Bloomberg, Breakthrough Therapy, Catalyst Pharmaceutical Partners, Chiesi, Chiesi Farmaceutici, EMA, FDA, Flemming Ornskov, Human Genetic Therapies, Jean-Jacques Bienaimé, Kamada, Kyprolis, life sciences, lysosomal storage diseases, M&A, Nexavar, NPS Pharmaceuticals, Onyx, Orphan drugs, pharmaceutical industry, rare diseases, regenerative medicine, Roche, San Francisco, Sarepta, Shire, speciality pharma, Ugo di Francesco, uniQure, Zymenex
Leave a comment
Soaring biotech equity heightens recruitment challenges
Authored by Karl Simpson
Posted in M&A Finance and Funding, Pharmaceutical business, Recruitment Market
Tagged Allergan, Amgen, AVI Biopharma, Biogen IDEC, biopharmaceuticals, biotechnology, celgene, challenges, emerging, Equity, europe, Genzyme, Gilead, IPO, liquidity, M&A, patent cliff, patent expirations, Prosensa, PTC Therapeutics, recruitment, Sarepta, Shire, USA
Leave a comment